Nordion to evaluate TheraSphere in PhIII

Nordion has received FDA approval to conduct a Phase III clinical trial to evaluate TheraSphere under an investigational device exemption as a treatment for colorectal cancer patients whose disease has metastasized to the liver. This randomized clinical trial, known as the EPOCH study, will take place at up to 30 sites worldwide and enroll approximately 350 patients.

EPOCH will examine a number of safety and efficacy endpoints in patients who have developed liver tumors from colorectal cancer and who have failed first-line chemotherapy. Participants in the treatment group will receive both TheraSphere and second-line chemotherapy, while patients in the control group will only receive the chemotherapy regimen, according to a company statement.

According to the U.S. National Cancer Institute, colorectal cancer is the third most common cancer in both men and women. An estimated 60 percent of CRC patients will eventually develop liver tumors. Most deaths associated with CRC are due to inoperable liver tumors, the company says.

- see the Nordion release

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.